Overview

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dacarbazine